Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 163 for:    ISOTRETINOIN

A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02498288
Recruitment Status : Completed
First Posted : July 15, 2015
Last Update Posted : June 12, 2017
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
This is an open-label, crossover, randomized, single dose, three treatments, three periods and six sequences, single dosage, balanced study to determine Bioequivalence of Isotretinoin. Bioequivalence will be compared between the reference medication one (T1) vs the test medication (T3): (T1 vs T3); and the reference medication two (T2), vs test medication (T3): (T2 vs T3). Finally, treatments T1 vs T2 will be compared statistically to determine if they are bioequivalent.

Condition or disease Intervention/treatment Phase
Acne Vulgaris Drug: Isotretinoin: Reference Medication 1 Drug: Isotretinoin: Reference Medication 2 Drug: Isotretinoin: Test Medication Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bioequivalence Study for an Isotretinoin Pharmaceutical Preparation - Capsules. Open, Crossover, Randomized, Single Dose, Three Treatments, Three Periods and Six Sequences With Meal (Breakfast) Study
Actual Study Start Date : May 31, 2013
Actual Primary Completion Date : July 15, 2013
Actual Study Completion Date : July 15, 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Isotretinoin Arm
All subjects in this study will be randomized to receive all the 3 distinct medications of isotretinoin in a sequential manner. Subjects will receive a single dosage of two capsules x 20 mg (40 mg) orally, for three periods, six sequences, with a wash-out period of two weeks to eliminate the first dosage.
Drug: Isotretinoin: Reference Medication 1
Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)

Drug: Isotretinoin: Reference Medication 2
Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)

Drug: Isotretinoin: Test Medication
Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.




Primary Outcome Measures :
  1. Area under the plasma concentration-time curve from zero hours to last quantifiable time (AUC0-t) [ Time Frame: Pre-dose and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 60.0, 72.0 and 96.0 hours post dose in each treatment period ]
    Bioequivalence will be evaluated for isotretinoin 40 mg using three distinct medications; two assigned as reference medication (T1 and T2) and 1 test medication (T3). Each subject will receive 2 capsules (20 mg each) orally.

  2. Area under the plasma concentration-time curve from zero hours to infinite (AUC0-infinity) [ Time Frame: Pre-dose and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 60.0, 72.0 and 96.0 hours post dose in each treatment period ]
    Bioequivalence will be evaluated for isotretinoin 40 mg using three distinct medications; two assigned as reference medication (T1 and T2) and 1 test medication (T3). Each subject will receive 2 capsules (20 mg each) orally.

  3. Maximum drug concentration (Cmax) [ Time Frame: Pre-dose and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 60.0, 72.0 and 96.0 hours post dose in each treatment period ]
    Bioequivalence will be evaluated for isotretinoin 40 mg using three distinct medications; two assigned as reference medication (T1 and T2) and 1 test medication (T3). Each subject will receive 2 capsules (20 mg each) orally.

  4. Time to maximum drug concentration (Tmax) [ Time Frame: Pre-dose and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 60.0, 72.0 and 96.0 hours post dose in each treatment period ]
    Bioequivalence will be evaluated for isotretinoin 40 mg using three distinct medications; two assigned as reference medication (T1 and T2) and 1 test medication (T3). Each subject will receive 2 capsules (20 mg each) orally.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Included in study will be male volunteers.
  • Ages between 18 and 45 years old.
  • BMI (Body Mass Index) between 20 to 26 kilogram/meter square (kg/m^2).
  • Anti-doping tests negative results.
  • Negative test results for Ac human immunodeficiency virus (HIV), HBsAg (hepatitis B surface antigen), and rapid plasma regain (RPR; syphilis test).
  • Clinical biochemical test values: Hematic Biometry, Urine Analysis, Biochemical Profile: (Glucose, Ureic Nitrogen, Urea, Creatinine, Uric Acid, Cholesterol, Triglycerides, Total Proteins, Albumin, Globulin, Bilirubin (total, indirect and direct), Alkaline Phosphatase (ALP), Lactic Dehydrogenase, Asparate aminotransferase (AST), Alanine aminotransferase (ALT), Calcium, Phosphorus, Sodium, Potassium, Chlorine and Iron), Ac HIV, HBsAg and RPR, must fall within an interval between minimum and maximum values in connection to said tests accepted values.
  • Normal Electrocardiogram (ECG) and Chest X-rays.
  • Complete the scale 'Columbia Suicide Severity Rating Scale' (C-SSRS), before and after each dosification period.
  • Obtain a grade of zero in the C-SSRS.
  • Signed the Informed Consent corresponding to the bioequivalence study.
  • In exception cases, accepted may be a candidate for which any previously mentioned test is exceeded regarding considered valid maximum and minimum accepted normal values, as long as it involves an isolated value and there are no other manifestations which could allow assuming that a given value is related to a disease or is remnant of another. These cases must be approved by clinical area and declared as "Non-clinically significant".

Exclusion Criteria:

  • Electrocardiographic Anomalies; radiological
  • Anti-doping tests positive results,
  • Positive results regarding RPR; HIV and HBsAg tests.
  • Personal or family history of allergy to medication in question.
  • Having any kind of allergy, since these persons are in higher risk of suffering from medication allergy.
  • Tobacco use.
  • Persons undergoing any medical treatment.
  • Existence of concurrent or intercurrent disease.
  • History psychiatric disorder (eg, Major Depressive Disorder, Generalized Anxiety Disorder, Bipolar Disorder (I or II), or schizophrenia).
  • Existence of justified doubt regarding questionnaire answers truthfulness.
  • Having participated in bioequivalence or bioavailability studies or having donated blood 2 months before the study.
  • Presence of clinically important gastrointestinal diseases or malabsorption history during the last year.
  • Presence of a medical condition requiring regular medication (with prescription or over-the- counter medication) with systemic absorption.
  • Drugs or alcohol addiction history requiring treatment.
  • Refuse to take the scale 'C-SSRS, before and after each dosification period.
  • Obtain a grade greater than zero in the C-SSRS.
  • Do not sign the Informed Consent corresponding to the bioequivalence study.
  • Finally, excluded will be all those volunteers not meeting that established in Mexican Official Standard NOM-177-SSA1-1998.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02498288


Locations
Layout table for location information
Mexico
GSK Investigational Site
Monterrey, Nuevo León, Mexico, 64600
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline

Additional Information:
Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT02498288     History of Changes
Other Study ID Numbers: 200115
First Posted: July 15, 2015    Key Record Dates
Last Update Posted: June 12, 2017
Last Verified: June 2017
Keywords provided by GlaxoSmithKline:
capsule
Isotretinoin
Bioequivalence
Additional relevant MeSH terms:
Layout table for MeSH terms
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
Isotretinoin
Dermatologic Agents